Tocilizumab every other week vs placebo + 52‐week taper
Proportion of participants with relapse‐free survival at ≥ 12 months · adults aged over 50 years with giant cell arteritis
Tocilizumab every other week probably leads to higher proportion of participants with relapse‐free survival at ≥ 12 months compared with placebo + 52‐week taper (moderate certainty).
1 finding from 1 review
- RR 1.48 [1.08, 2.03]1 study · 100 participantsModerate